Dogwood Therapeutics (DWTX) Other financing activities (2021 - 2026)
Dogwood Therapeutics (DWTX) posted Other financing activities of $23.0 for Q2 2026, down 82.58% on a QoQ basis from $132.0 in Q1 2026.
Powered by 
Analysis
Dogwood Therapeutics (DWTX) Other financing activities (2021 - 2026) Analysis & Trends
Dogwood Therapeutics has reported Other financing activities for 3 years, with the latest figure at $23.0 in Q2 2026.
- On a quarterly basis, Other financing activities changed N/A year-over-year to $23.0 in Q2 2026; TTM through Jun 2026 was -$578568.0, a N/A change from a year earlier, with the FY2022 full-year figure at $4.5 million, up 1621.38% from the prior year.
- Other financing activities was $23.0 for Q2 2026 at Dogwood Therapeutics, down from $132.0 in the prior quarter.
- The five-year high for Other financing activities was $132.0 in Q1 2026, with the low at -$85995.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Dogwood Therapeutics | 65.53 Mn | 65.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.00 |
| Mar 31, 2026 | 132.00 |
| Dec 31, 2022 | -85,995.00 |
| Dec 31, 2021 | -492,728.00 |
| Mar 31, 2021 | 197,562.00 |